Condor Capital Management Decreases Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Condor Capital Management decreased its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,632 shares of the company’s stock after selling 237 shares during the period. Condor Capital Management’s holdings in HCA Healthcare were worth $4,392,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in HCA. GSA Capital Partners LLP purchased a new position in shares of HCA Healthcare in the third quarter worth $567,000. Quest Partners LLC raised its holdings in shares of HCA Healthcare by 384.9% in the third quarter. Quest Partners LLC now owns 3,171 shares of the company’s stock worth $1,289,000 after buying an additional 2,517 shares during the last quarter. Pathstone Holdings LLC increased its stake in shares of HCA Healthcare by 23.1% in the third quarter. Pathstone Holdings LLC now owns 27,589 shares of the company’s stock worth $11,213,000 after acquiring an additional 5,175 shares during the period. Prospera Financial Services Inc increased its stake in shares of HCA Healthcare by 204.2% in the third quarter. Prospera Financial Services Inc now owns 2,917 shares of the company’s stock worth $1,186,000 after acquiring an additional 1,958 shares during the period. Finally, Banque Cantonale Vaudoise increased its stake in shares of HCA Healthcare by 25.6% in the third quarter. Banque Cantonale Vaudoise now owns 12,187 shares of the company’s stock worth $4,953,000 after acquiring an additional 2,481 shares during the period. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

NYSE:HCA opened at $334.42 on Thursday. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. The company’s 50-day moving average price is $320.53 and its 200-day moving average price is $343.97. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $417.14. The company has a market cap of $82.34 billion, a P/E ratio of 15.22, a P/E/G ratio of 1.10 and a beta of 1.68.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same quarter in the prior year, the firm earned $5.90 EPS. On average, sell-side analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 17th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.86%. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.66. The ex-dividend date of this dividend is Monday, March 17th. HCA Healthcare’s payout ratio is 13.11%.

Wall Street Analysts Forecast Growth

HCA has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 price objective on shares of HCA Healthcare in a research note on Monday, January 27th. Barclays dropped their price target on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Truist Financial dropped their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Wells Fargo & Company lowered shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $400.00 to $320.00 in a research report on Monday, November 25th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $380.00 price target on shares of HCA Healthcare in a research report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $385.67.

Insider Activity

In other news, SVP Jennifer Berres sold 9,533 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $322.59, for a total value of $3,075,250.47. Following the sale, the senior vice president now directly owns 15,412 shares of the company’s stock, valued at approximately $4,971,757.08. The trade was a 38.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.